Skip to search formSkip to main contentSkip to account menu

elagolix

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Hydrocarbons, FluorinatedPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the… 
2019
2019
Elagolix (Orilissa) for Endometriosis Pain.
Elagolix can decrease pain in women with endometriosis, but it is expensive and has adverse effects similar to those of other… 
2019
2019
Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials.
2019
2019
Elagolix Treatment in Women With Uterine Fibroids: Secondary, 6-Month, Phase 3 Efficacy Results [11J]
METHODS: Multicenter, open-label trial in sexually active females $15 years seeking contraception were administered LF111 (4.0 mg… 
2018
2018
Elagolix Reduces Fatigue in Patients With Moderate-to-Severe Endometriosis Pain [34G]
INTRODUCTION:Endometriosis-associated symptoms like menstrual and non-menstrual pelvic pain can be associated with fatigue. This… 
Review
2018
Review
2018
New Horizons in Fibroid Management
Purpose of ReviewReview of the latest advances in the treatment of uterine fibroids. Addressing conservative management, medical… 
2018
2018
When Is Milk Really Milk?
  • R. Voelker
  • Journal of the American Medical Association (JAMA…
  • 2018
  • Corpus ID: 52174143
Review
2017
Review
2017
A peek into the drug development scenario of endometriosis - A systematic review.
2011
2011
Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis
compared to the E2 decrease. In addition, within the range of acceptable 6-month BMD changes (e.g., 0.8% up toward 1.6%), there… 
2008
2008
Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide GnRH Antagonist Elagolix
ABSTRACT Context: Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis, fibroids… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)